Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects-Reference-Cited by-同舟云学术

Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects

Published:2015-09-12 Issue:11 Volume:71 Page:1365-1374
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Morrison Mary,Palermo Guiseppe,Schmitt Christophe

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-015-1938-4.pdf

Reference14 articles.

1. Kling D, Stucki C, Kronenberg S, Tuerck D, Réaume E, Tardif JC, Gaudreault J, Schmitt C (2013) Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab—preclinical and clinical studies. Thromb Res 131(5):401–410

2. Tardif JC, Tanguay JF, Wright SS, Duchatelle V, Petroni T, Grégoire JC, Ibrahim R, Heinonen TM, Robb S, Bertrand OF, Cournoyer D, Johnson D, Mann J, Guertin MC, L’Allier PL (2013) Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST elevation myocardial infarction results of the SELECT-ACS Trial. J Am Coll Cardiol 61(20):2048–2055

3. Schmitt C, Abt M, Ciorciaro C, Kling D, Jamois C, Schick E, Solier C, Benghozi R, Gaudreault J (2015) First in man study with inclacumab, a human monoclonal antibody against P-selectin. J Cardiovasc Pharmacol 65(6):611–619

4. Schmitt C, Mudie N, Ciorciaro C, Gaudreault J (2015) Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers. J Cardiovasc Pharmacol 65(4):386–392

5. Multiple ascending dose study of inclacumab in healthy volunteers and patients with peripheral arterial disease. https://www.clinicaltrials.gov/ct2/show/NCT00760565

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving treatment landscape for children with sickle cell disease;The Lancet Child & Adolescent Health;2023-11

2. A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease;European Journal of Clinical Pharmacology;2023-07-12

3. Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics;Expert Opinion on Biological Therapy;2022-11-02

4. Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?;Clinical Pharmacology in Drug Development;2021-11-26